Torsten Hoffmann

Torsten Hoffmann is a member of the American Chemical Society and the Swiss Chemical Society.
He was the Managing Director & Chief Scientific Officer at Proteros biostructures GmbH.
He was also the Head-Global Roche Postdoc at Roche Holding AG from 1999 to 2015.
In 2017 to 2018, he was the Chief Operating Officer at Silence Therapeutics Plc.
He was an Associate at The Scripps Research Institute and the Chief Scientific Officer at Oryzon Genomics SA. He was also the Chief Scientific Officer & Executive VP at Zealand Pharma A from 2013 to 2015.
Dr. Hoffmann holds a doctorate degree from the Swiss Federal Institute of Technology.
Currently, he holds positions as a member of the American Chemical Society and the Swiss Chemical Society.